TScan Therapeutics raises $30M via registered direct offering of pre-funded warrants to Lynx1 Capital

TScan Therapeutics, Inc.

Entered securities purchase agreement for pre-funded warrants to purchase 7.5M shares at $4.00 per warrant, gross proceeds ~$30M.
Purchaser is Lynx1 Capital Management LP and an affiliated fund, an existing shareholder.
Net proceeds ~$29.8M for general corporate purposes; closing expected Dec 27, 2024.
Cash runway extended into Q1 2027 based on net proceeds.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.